granada

Pomegranate (Punica granatum L.): A Comprehensive Reference

1. Identity and Botanical Classification

Botanical and Chemical Nomenclature

Pomegranate (Punica granatum L.) belongs to the Lythraceae family and is a historic fruit indigenous to Central Asia, found in places such as the Middle East, Iran, and Turkmenistan to northern India. It is a fruit-bearing shrub or small tree that grows up to about 5–7 meters with very diverse varieties. Two prominent species of pomegranate exist — Punica protopunica and Punica granatum L. — the latter being generally known as "Anar" and farmed worldwide.

Its adaptability and resilience have enabled it to thrive across various agro-climatic regions, with primary cultivation in India, Iran, China, the USA, and Turkey. Pomegranates mainly originated in Persia, the center of the Middle Eastern region, then spread to Mediterranean regions, mainly India and China. Early cultivation was in Ancient Egypt, Greece, Italy, and Iraq, and later spread to Asian countries, particularly Turkey, Afghanistan, Iran, India, and China.

Common Forms and Preparations

Different parts of pomegranate — including seed, peel, juice, and leaves — are rich in potential bioactive compounds. In commerce and research, pomegranate appears in several distinct forms:

• Pomegranate juice (PJ): Pressed from the arils; the most widely consumed and studied form.
• Pomegranate extract (PE): A concentrated form of juice obtained from the pomegranate fruit, commonly marketed as a dietary supplement due to its potential health benefits, including antioxidant, anti-inflammatory, and antibacterial properties. Extracts are frequently standardized to contain 30% punicalagins, which are the active compounds responsible for their antioxidant potential.
• Pomegranate seed oil: Derived from cold-pressing the seeds and containing high levels of the unique fatty acid punicic acid.
• Peel preparations: Pomegranate peel encompasses approximately 30–40% of the fruit's total weight and is processed into powders, extracts, and gel preparations.
• Mouthwash / topical gel: Aqueous or hydroalcoholic preparations of peel or whole fruit extract used in oral health applications.

The "Wonderful" variety is the most studied for its significant bioactive compounds, while other notable varieties like Gabsi, Mollar de Elche, Ganesh, Nana, and Ruby have also demonstrated substantial bioactive potential, particularly in in vitro studies. However, variability in phytochemical composition due to different extraction methods and environmental conditions poses challenges for standardization.

---

2. Traditional and Historical Use

Ancient Mediterranean and Near Eastern Traditions

Since ancient times (4000–3000 BCE), pomegranate has been familiar to people across different civilizations. It has bloomed as a symbol of life, permanence, well-being, femaleness, fertility, knowledge, immortality, and holiness. It has also been extensively used as a folk medicine in many cultures, documented at least as early as circa 1550 BCE in the Egyptian Ebers Papyrus.

According to Pliny the Elder, a first-century naturalist, the plant was a cure-all and had the power to alleviate a wide variety of health concerns. Pliny listed it as a key ingredient for twenty-six different remedies.

Punica granatum L. is one of the Mediterranean medicinal plants that has been used for generations in treating ulcers, diarrhea, and male infertility.

Islamic and Persian (Iranian) Traditional Medicine

In Islamic and Iranian Traditional Medicines (ITM), this valuable plant was used by traditional physicians in various preparations and diverse application forms for a wide variety of illnesses. They used different parts of the plant — mainly fruit peels, fruit juice, and flowers — for health problems such as skin diseases, reproductive problems, gastrointestinal disorders, infectious diseases, and respiratory problems.

Based on traditional textbooks, pomegranate has beneficial effects on diseases related to gastrointestinal, upper and lower respiratory, visual, and reproductive systems. In addition, pomegranate and its preparations have been prescribed for treating metabolic disorders, skin problems, and wounds as well as dental protection.

Ayurvedic Tradition

According to Ayurveda, the pomegranate tree is an excellent pharmacopoeia. Ayurveda medicine uses not only the seeds, but also the flowers, the rind of the fruit, and the root bark. Every part of the plant has its own qualities and, consequently, specific healing properties: the fresh fruit juice is considered a powerful tonic, particularly for the digestive and circulatory systems; the skin is said to have anti-inflammatory properties and is thereby used to treat sore conditions. Ayurveda medicine uses pomegranates to treat around one hundred different conditions.

Traditional Chinese and Other Asian Traditions

The first documented medicinal use of various pomegranate parts, including the peel, seeds, flowers, leaves, and roots, dates back to the Han Dynasty, as recorded in Min-Yi-Bie-Lu. Therefore, pomegranate has a very long history of use not only in traditional Chinese medicine but also in diverse clinical practices among Tibetans, Uyghurs, Miaos, and other ethnic groups.

In Tibetan medicine, ground pomegranate seeds mixed with Chinese cinnamon, galangal, cardamom, and long pepper are a remedy to stimulate digestion. Pomegranate also finds clinical application in Hmong medicine for treating conditions such as chronic diarrhea, dysentery, and roundworms. Furthermore, pomegranate flowers are used to treat nosebleeds, while whole pomegranate dried fruit is used in Mongolian medicine for treating conditions such as gastritis, indigestion, and abdominal distension.

The Pharmacopoeia of the People's Republic of China (2020 edition) acknowledges the efficacy of pomegranate peel in astringent and antidiarrheal, hemostatic, and anthelmintic capacities.

Pomegranate appears in Ayurvedic and ancient traditional Chinese medicine with properties and uses that are similar, if not identical, to those in the ancient Mediterranean world. In a traditional narrative, pomegranate (as a part of the body of Greek medical literature) reached these worlds through the Arabic world, where its use reproduced those of ancient Greece since the Greek medical literature of antiquity was translated into Arabic between the late 9th century and the 11th century.

---

3. Key Constituents and Active Compounds

Overview of Phytochemical Classes

Active compounds isolated from pomegranate include alkaloids, anthocyanidins, tannins, flavonoids, phenolics, proanthocyanidins, sterols, terpenes, terpenoids, xanthonoids, fatty acids, organic acids, lignans, saccharides, and vitamin C.

More specifically, pomegranate contains sinapyl, coniferyl, ellagic acid, cinnamic acid, genistein, linoleic acid, anthocyanin, gallic acid, catechin, quercetin, rutin, kaempferol, cyanidin, punicalin, delphinidin, punicalagin, chlorogenic acid, coumaric acid, luteolin, and pelletierine alkaloids, flavonoids, anthocyanin, and caffeic acid.

A group of phytoestrogens (plant lignans) and phytosterols (triterpenoids) have also been identified in pomegranate, as well as tryptamine, melatonin, serotonin, various other alkaloids, and medium- and very long-chain fatty acids.

Distribution by Plant Part

The peel is particularly rich in ellagitannins, especially punicalagin and punicalin; arils and juices are enriched in anthocyanins and flavonols; and seed oil contains high levels of punicic acid.

Mass spectrometry analysis has revealed that the most prevalent compounds in pomegranate peels are punicalagin, granatin, and their derivatives.

Signature Compounds

• Punicalagin: Punicalagin, a hydrolyzable ellagitannin, accounts for more than half of the antioxidant effects of pomegranate.
• Ellagitannins and Ellagic Acid: Ellagitannins (ETs) are the most abundant polyphenols present in pomegranate juice and contribute greatly towards its reported biological properties. ETs are not absorbed intact but are partially hydrolyzed in the gut to ellagic acid (EA). Colonic microflora can convert EA to urolithin A (UA), and EA and UA enter the circulation after pomegranate juice consumption.
• Urolithins: Gut microbiota-driven conversion of ellagitannins and ellagic acid into urolithins is a major determinant of systemic bioactivity and may contribute to interindividual variability in response. Ellagitannins are ultimately converted by the gut microbiome into urolithins.
• Anthocyanins: Pigments concentrated in the juice and arils responsible for the deep red color and contributing to antioxidant activity.
• Punicic Acid: A conjugated linolenic acid (C18:3) uniquely concentrated in pomegranate seed oil.

The biological activities of pomegranate appear to result from synergistic interactions among multiple bioactive compounds rather than from a single dominant constituent. The synergistic effect of these various compounds has been shown to increase their bioactivity.

Nutritional Composition

In addition to its rich phytochemical profile, pomegranate emerges as a nutritionally rich fruit, boasting significant quantities of vitamins C and D, magnesium, potassium, and dietary fibers.

---

4. Mechanisms of Action

Key Signaling Pathways

The mechanisms of action of pomegranate mainly involve nuclear factor-erythroid factor 2-related factor 2 (Nrf2), nuclear factor kappa B (NF-κB), and mitogen-activated protein kinase (MAPK) signaling pathways. Nrf2 activation underpins antioxidant gene expression, while NF-κB inhibition mediates the anti-inflammatory effects. MAPK pathway modulation contributes to anti-proliferative effects in cancer cell models.

Antioxidant Activity

Among polyphenol-rich foods, pomegranate stands out for its potent antioxidant activity and unique bioactive compounds such as punicalagin, ellagic acid, and anthocyanins. Notably, its antioxidant activity is approximately 3 times greater than that of red wine or green tea, making it particularly effective.

Anti-inflammatory Activity

Pomegranate's anti-inflammatory properties are mediated principally through inhibition of NF-κB, thereby reducing the transcription of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). Reported biological activities include antioxidant, anti-inflammatory, antimicrobial, metabolic, anti-aging, and anticancer effects.

Gut Microbiota and Urolithin Production

Punica granatum L. is an abundant source of polyphenols, including hydrolyzable ellagitannins, ellagic acid, anthocyanins, and other bioactive phytochemicals effective in defending against oxidative stress and with immunomodulatory activities. Ellagitannins, and their hydrolyzed product ellagic acid, interact with the gut microbiota to yield secondary metabolites known as urolithins that may have health benefits.

Anti-cancer Mechanisms

Ellagitannin inhibited the expression of androgen receptor (AR) and androgen synthesizing enzymes, such as 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) and steroid 5α reductase type I (SRD5A1), in prostate cancer cells. Ellagic acid was shown to possess anti-tumorigenic activities on lung, cervical, colon, breast, and prostate cancer cells. Ellagic acid and its metabolite urolithin A synergistically inhibited cell growth and induced apoptosis in DU145 and PC3 cells.

Antimicrobial Mechanisms (Oral)

Pomegranate has several antimicrobial ingredients and exerts antibacterial effects through several mechanisms. Punicalagin and ellagitannin impair the synthesis of polyglycans and prevent the adhesion of microorganisms to the tooth surface. Furthermore, tannins pass through the cell wall, adhere to the cell membrane, and cause protein deposition and suppression of enzymes such as glycosyltransferase.

---

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health: Blood Pressure

Randomized clinical trials (RCTs) which studied the effects of pomegranate consumption on blood pressure have shown inconsistent findings. A systematic review and meta-analysis searched electronic databases including PubMed, Web of Science, and Scopus up to January 2024 for eligible RCTs. Individuals with baseline systolic blood pressure (SBP) >130 mmHg had a significantly greater reduction in SBP compared to individuals with baseline SBP <130 mmHg. There was a high level of heterogeneity among studies (SBP: I² = 90.0% and DBP: I² = 91.8%). Overall, the results demonstrated that pomegranate consumption lowered SBP and DBP in adults. Although the results suggest that pomegranate juice may be effective in reducing blood pressure in the pooled data, further high-quality studies are needed to demonstrate the clinical efficacy of pomegranate consumption.

At the individual trial level, a total of fifty-five participants enrolled in a randomized double-blinded placebo-controlled clinical trial where they were assigned to either pomegranate extract (PE) capsules or placebo capsules for 8 weeks. Blood pressure, body weight, waist circumference, waist:hip ratio, and body composition were measured at baseline, week 4, and week 8. Results showed a significant decrease in diastolic blood pressure after 8 weeks (by 2.79 mmHg; P < 0.05), while the decrease in systolic blood pressure did not reach statistical significance.

Evidence strength: Moderate. Multiple RCTs and a pooled meta-analysis indicate blood pressure-lowering potential, but the high between-study heterogeneity and small individual trial sizes limit definitive conclusions. Effects appear stronger in individuals with elevated baseline blood pressure.

5.2 Cardiovascular Health: Lipid Profile and Metabolic Syndrome

A systematic review of clinical studies published in Nutrients (2022) searched PubMed, EMBASE, MEDLINE, Google Scholar, Cochrane, and ClinicalTrials.gov for trials associating any part of P. granatum with metabolic syndrome (MetS) risk factors. Of studies meeting criteria, only 20 were included in the qualitative analysis. The included studies suggest that pomegranate can be beneficial to reduce body weight, blood pressure, glycemia, triglycerides, total cholesterol, and low-density lipoprotein cholesterol. Moreover, it can augment high-density lipoprotein cholesterol levels and improve insulin resistance. Although relevant effects were observed, additional well-designed clinical trials are needed to determine the correct formulations and doses to prevent or treat MetS components.

Consumption of pomegranate juice has been shown to have preventive roles in obesity, metabolic syndrome, and coronary heart disease, which is believed to be due to its potent antioxidant properties.

Evidence strength: Preliminary to moderate. Findings across the 20 included clinical trials were generally positive for multiple MetS markers, but study heterogeneity, small sample sizes, and variable intervention durations temper the strength of conclusions.

5.3 Inflammation and Oxidative Stress

A 2025 double-blind parallel randomized controlled trial enrolled 86 adults aged 55–70 years. Participants received either placebo capsules (maltodextrin) or pomegranate extract (740 mg) daily for 12 weeks. At baseline, week 6, and week 12, anthropometric measurements, blood pressure, and blood samples were collected. Serum inflammatory markers (IL-6, IL-1-α, IL-1β, IL-2, TNF-α, CRP, and PAI-1), fasting blood glucose, and lipid levels were measured. A total of 76 participants completed the trial. A significant interaction between treatment and time was observed for IL-6 (p = 0.02) and IL-1β (p = 0.05) levels, with both parameters significantly decreasing in the PE group.

A meta-analysis of 16 randomised clinical trials reported the effect of pomegranate in reducing inflammatory markers. However, findings are limited by the short duration of several studies (fewer than 12 weeks), the heterogeneous population characteristics, and the lack of focus on prevention in older adults.

Evidence strength: Moderate. RCT evidence for reductions in IL-6 and IL-1β is emerging, but short study durations and heterogeneous populations limit generalizability.

5.4 Prostate Cancer and PSA Doubling Time

A phase II clinical trial demonstrated that pomegranate juice (PJ) increases prostate-specific antigen (PSA) doubling time in prostate cancer (CaP) patients with a rising PSA. In that trial, pomegranate juice consumption by prostate cancer patients with rising PSA following primary therapy significantly increased the mean PSA doubling time from 15 to 54 months (p < 0.001).

Regarding the mechanism, on consumption, ellagitannins hydrolyze to release ellagic acid (EA), which is then converted by gut microflora to urolithin A (UA) derivatives. Ellagitannin, the most abundant polyphenol present in pomegranate juice, is hydrolyzed to ellagic acid (present at about 50–200 µg/mL in juice) that is then converted to urolithin A by gut microflora.

Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer. In the BCR patient population, early phase II trials of both pomegranate juice and extract showed significant lengthening of PSA doubling time, and confirmed the safety of pomegranate products.

In men with prostate cancer, the administration of 8 ounces of pomegranate juice by mouth daily (Wonderful variety, equivalent to 570 mg total polyphenol gallic acid equivalents daily) slowed down the blood increment of prostate-specific antigen (PSA), a well-known marker of cancer progression.

Evidence strength: Preliminary but clinically notable. Phase II trials show a significant prolongation of PSA doubling time. However, phase II trials lack a placebo-controlled arm sufficient to confirm causation, and larger controlled trials are needed to establish clinical benefit. The results are hypothesis-generating, not practice-changing.

5.5 Diabetes, Glycemic Control, and Endothelial Function

The major pharmacological effects of pomegranate reported in randomized clinical trials pertain to diabetes, cardiovascular disease, oral cavity disorders, endocrine disorders, and cancer.

A systematic review focusing specifically on oxidative stress, inflammation, and endothelial function in diabetes searched PubMed, Scopus, and Google Scholar and analyzed 46 relevant studies from an initial pool of 170. The analyzed evidence suggests that pomegranate has the potential to alleviate oxidative stress, inflammation, and endothelial dysfunction in diabetes. Although a beneficial impact was noted in these markers, the endothelial function evidence still requires validation through further clinical trials with a powered sample size.

In diabetes, the hypoglycemic effect of pomegranate juice or other compounds is limited, but its antioxidative effect has been demonstrated. Conflicting reports still exist regarding its effects in diabetes.

Evidence strength: Preliminary to moderate. Pomegranate shows consistent positive signals for oxidative stress and inflammation markers in diabetic populations, but direct glycemic effects are limited and inconsistent across trials.

5.6 Oral Health: Plaque, Gingivitis, and Periodontitis

A clinical trial was conducted on 30 healthy volunteers aged 25–30 years who visited a dental outpatient department. Before conducting the study, thorough oral prophylaxis was done and subjects were asked to refrain from oral hygiene procedures for 24 hours. Dental plaque was collected from each subject before and after rinsing 30 mL of pomegranate juice without sugar. Results showed that pomegranate rinse was effective against dental plaque microorganisms. There was a significant reduction in the number of colony-forming units of streptococci (23%) and lactobacilli (46%).

The beneficial effects of pomegranate mouthwash or gel on periodontitis, gingivitis, and stomatitis are likely related to its anti-inflammatory, antioxidant, and antimicrobial activities. In a randomized double-blind controlled trial on 84 patients, pomegranate peel extract lozenge showed significant reduction in gag reflex within dental procedures. The effect of P. granatum mouthwash (140 mL as a daily rinse after breakfast and before sleeping) on salivary Streptococcus mutans level was assessed in 60 children. After seven days, all of the respective mouthwashes revealed statistically significant decline in S. mutans and plaque index levels.

A 38% pomegranate mouthwash had a comparable efficacy to chlorhexidine in reduction of dental plaque. Further clinical trials and in vivo studies are needed to fully understand the optimal formulations, dosages, and long-term effects of Punica granatum in dental care.

Evidence strength: Moderate for short-term antimicrobial and antiplaque effects. Multiple small clinical trials show consistent reductions in plaque microorganisms and gingival inflammation. Head-to-head comparisons with chlorhexidine are promising but limited by small sample sizes and short durations.

5.7 Exercise Recovery and Muscle Damage

Pomegranate supplementation has been shown to reduce oxidative stress and inflammation, with some evidence suggesting it may accelerate recovery from exercise-induced muscle damage (EIMD), including metabolic, mechanical, and neuromuscular recovery.

A 2025 systematic review and meta-analysis registered with PROSPERO (CRD42024536905) searched Scopus, PubMed, and Web of Science up to January 2024 for studies evaluating pomegranate supplementation and exercise recovery in athletes and non-athletes aged 18–55. Ten studies were included in the meta-analysis. Lactate dehydrogenase (LDH) is a well-established marker of cellular damage, and its reduction suggests that pomegranate supplementation may help preserve muscle cell integrity by mitigating oxidative stress and inflammation. Lactate concentrations were similarly unaffected by pomegranate supplementation, corroborating findings from a previous systematic review that showed minimal effects on lactate clearance. The lack of significant effects on lactate concentrations suggests that pomegranate's benefits are not primarily mediated through anaerobic metabolic recovery but may involve other pathways, such as oxidative stress reduction.

Evidence strength: Preliminary. The meta-analysis of 10 studies suggests some benefit for oxidative-stress-mediated EIMD markers, but effects on direct markers of neuromuscular recovery are inconsistent. Study populations, dosing, and exercise protocols vary considerably.

5.8 Gut Microbiota

A randomized, double-blind, placebo-controlled study conducted over 4 weeks on healthy volunteers aged 25–55 years examined the effects of a standardized punicalagin-enriched pomegranate extract. The objective was to determine the effects of supplementation with Pomella® (250 mg) on the gut microbiome, circulating short-chain fatty acids, and urolithins. Subjects were randomly assigned to receive either an oral supplement containing 75 mg of punicalagin or an oral placebo. Pomegranate extract (450 mg) and pomegranate juice (25 µg/mL) increased the relative abundance of beneficial bacteria such as Bifidobacterium by 20% and 15%, respectively, in an in vitro fecal culture study. Both agents also increased mean counts of Lactobacillus.

Evidence strength: Preliminary. In vitro and animal data are encouraging, but human RCT evidence for meaningful gut microbiota modulation by pomegranate supplementation is limited and requires replication in larger trials.

5.9 Other Areas Under Investigation

Some clinical trials have indicated that pomegranate can be consumed for alleviation of non-alcoholic fatty liver disease, metabolic syndrome, dental infections, and menopausal symptoms. Research focuses on biological activities of pomegranate's polyphenolic compounds — antioxidant, anti-inflammatory, antiproliferative, and antimicrobial — that can induce beneficial effects in internal medicine (such as in metabolic syndrome, cancer, urinary tract infections, nephrolithiasis, inflammatory bowel diseases, and neurodegenerative diseases) and in dentistry. Evidence in these additional areas ranges from preclinical to very early clinical, and none has sufficient RCT evidence to support specific clinical recommendations.

---

6. Body Systems Associated with Pomegranate

• Cardiovascular system: Blood pressure reduction, LDL cholesterol reduction, HDL augmentation, antioxidant protection of the vascular endothelium.
• Metabolic / endocrine system: Insulin resistance improvement, attenuation of oxidative stress in diabetes, triglyceride reduction.
• Gastrointestinal system: Traditional antidiarrheal and anthelmintic uses (peel); support of beneficial gut microbiota (Bifidobacterium, Lactobacillus); astringent and anti-inflammatory actions on the gut mucosa.
• Oncology: Prostate cancer — prolongation of PSA doubling time in early clinical trials; preclinical anticancer activity against lung, cervical, colon, and breast cancer cells.
• Oral cavity: Reduction of dental plaque, Streptococcus mutans, and Lactobacillus; improvement of gingivitis and periodontitis indices.
• Musculoskeletal / exercise: Attenuation of exercise-induced oxidative stress and muscle damage markers.
• Immune and inflammatory system: Reductions in IL-6, IL-1β, CRP, and TNF-α across multiple clinical trial populations.
• Skin: Pomegranate showed remarkable protective effects from ultraviolet (UV) irradiation, preventing ROS formation and inflammation, edema, hyperplasia, immunosuppression, photoaging, and skin cancer.

---

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported directly from peer-reviewed sources and systematic reviews:

• Pomegranate juice: Pomegranate juice in amounts ranging from 50 to 750 mL/day for various durations has been used in studies evaluating effects on cardiovascular disease risk factors.
• Pomegranate juice (prostate cancer): 8 ounces (approximately 240 mL) per day of the Wonderful variety, equivalent to 570 mg total polyphenols (gallic acid equivalents) daily.
• Pomegranate extract (exercise endurance): Pomegranate extract 750 mg/day (as two 375 mg capsules of Pomanox P30, containing 30% punicalagins) for 15 days has been used in a study evaluating effects on exercise endurance performance.
• Pomegranate extract (prostate cancer, extended): Pomegranate extract 1 g/day or 3 g/day (i.e., 1 or 3 capsules, with each capsule containing 1,000 mg of polyphenol extract, comparable to 240 mL or 720 mL of pomegranate juice, respectively) for up to 18 months was used in a trial evaluating effects on rising PSA levels in men with recurrent prostate cancer.
• Pomegranate extract (blood pressure/anthropometry): A total of 55 participants were assigned to either pomegranate extract (PE) capsules or placebo capsules for 8 weeks. (The exact dose in mg was not specified in retrieved excerpts.)
• Pomegranate extract (inflammation in older adults): Participants received either placebo capsules (maltodextrin) or pomegranate extract (740 mg) daily for 12 weeks.
• Pomegranate extract (radiotherapy skin protection): A study on patients treated with 2 capsules/day of 300 mg of pomegranate extract (containing 40% polyphenols and 27% punicalagin) for 6–7 weeks demonstrated protective effects in preventing radiotherapy damage at the skin level.
• Standardized extract (gut microbiome): Subjects received an oral supplement containing 75 mg of punicalagin or an oral placebo.
• Pomegranate mouthwash (dental): A pomegranate mouthwash used as 140 mL as a daily rinse after breakfast and before sleeping was assessed in 60 children for its effect on salivary Streptococcus mutans.

---

8. Safety Considerations and Drug Interactions

General Safety Profile

Subchronic administration of pomegranate fruit extract has been proven to be safe in rats. Based on research, the no-observed-adverse-effect level (NOAEL) for a standardized pomegranate fruit extract is determined to be 600 mg/kg body weight/day, indicating a broad spectrum of safety. The pomegranate fruit has been used for centuries with no toxic effects.

Pregnancy and Lactation

Use during pregnancy should be avoided. Information regarding safety and efficacy in pregnancy and lactation is lacking.

Drug Interactions: Warfarin

Observational studies reported that pomegranate juice (PJ) prolonged the pharmacodynamics of warfarin. Furthermore, since it has been shown that pomegranate constituents inhibit cytochrome P450 (CYP450) activities such as CYP3A4 and CYP2C9, PJ may affect intestinal and liver metabolism of CYP3A4 and CYP2C9-mediated drugs.

All combinations of pomegranate peel extract and warfarin enhanced the anticoagulant activity of warfarin, and the investigation confirmed serious drug-herb interactions between warfarin and pomegranate peel or guava leaf extracts. Such results might conclude a high risk of bleeding from the co-administration of the investigated herbal drugs with warfarin therapy.

Drug Interactions: Sildenafil

Observational studies reported that pomegranate juice prolonged the pharmacodynamics of sildenafil. Pomegranate juice can increase the effects of sildenafil.

Drug Interactions: CYP450 Substrates

Pomegranate constituents inhibit cytochrome P450 (CYP450) activities such as CYP3A4 and CYP2C9, meaning pomegranate juice may affect intestinal and liver metabolism of CYP3A4 and CYP2C9-mediated drugs. Significant reduction in CYP2C8, CYP2C9, and CYP3A4 was seen upon concomitant use of warfarin with ellagic acid. In contrast, some drugs exhibited no interaction with pomegranate, such as theophylline.

Standardization Challenges

Depending on the cultivar, growing area, maturity, cultivation technique, climate, and storage conditions, different portions of the pomegranate have distinct chemical compositions. This variability means that the polyphenol content of commercial juices and extracts may differ substantially from quantities used in clinical trials, making it difficult to translate research dosages to commercial products without standardization data.

---

References

• Unlocking the therapeutic treasure of pomegranate leaf: A comprehensive review on phytochemical compounds, health benefits, and future prospects — PMC
• Therapeutic Effects of Punica granatum (Pomegranate): An Updated Review of Clinical Trials — PMC
• A comprehensive review on phytochemistry, bioactivity and medicinal value of bioactive compounds of pomegranate (Punica granatum) — Advances in Traditional Medicine, Springer
• Phytochemical Diversity of Punica granatum L. and Its Multi-Target Biological Functions — Nutrients (MDPI), 2026
• Medicinal uses, pharmacological activities, phytochemistry, and the molecular mechanisms of Punica granatum L. — ScienceDirect
• Pomegranate (Punica granatum L.): A Fruitful Fountain of Remedial Potential — PMC
• Pomegranate: A review of the heavenly healer's past, present, and future — PMC
• A unique understanding of traditional medicine of pomegranate, Punica granatum L. and its current research status — ScienceDirect
• Pomegranate seeds: a comprehensive review of traditional uses, chemical composition, and pharmacological properties — PMC
• Herbs in History: Pomegranate — American Herbal Products Association
• Assessment of the Biological Activity and Phenolic Composition of Ethanol Extracts of Pomegranate (Punica granatum L.) Peels — PMC
• The effects of pomegranate consumption on blood pressure in adults: A systematic review and meta-analysis — PubMed
• Effect of pomegranate extract on blood pressure and anthropometry in adults: a double-blind placebo-controlled randomised clinical trial — PMC
• Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55–70 Years: A Randomised Controlled Parallel Trial — PMC
• Pomegranate (Punica granatum L.) and Metabolic Syndrome Risk Factors and Outcomes: A Systematic Review of Clinical Studies — PMC
• Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland — PubMed
• Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth — PMC
• Pomegranate and Its Components as Alternative Treatment for Prostate Cancer — PMC
• The Impact of Punica granatum Linn and Its Derivatives on Oxidative Stress, Inflammation, and Endothelial Function in Diabetes Mellitus — PMC
• Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review — PMC
• Critical pharmacokinetic and pharmacodynamic drug-herb interactions in rats between warfarin and pomegranate peel or guava leaves extracts — PMC
• Effect of Pomegranate Juice on Dental Plaque Microorganisms (Streptococci and Lactobacilli) — PMC
• A Natural Approach to the Prevention and Treatment of Gingivitis and Periodontitis: A Review of Pomegranate's Bioactive Properties — MDPI Life
• Effect of hydroalcoholic extract of whole pomegranate fruit on cariogenic bacteria and its clinical effect on dental plaque formation in children — PMC
• The Effects of Pomegranate Supplementation on Markers of Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis — PMC
• Prospective Randomized, Double-Blind, Placebo-Controlled Study of a Standardized Oral Pomegranate Extract on the Gut Microbiome and Short-Chain Fatty Acids — PMC
• An Overview of the Health Benefits, Extraction Methods and Improving the Properties of Pomegranate — PMC
• Review of Pharmacological and Medicinal Uses of Punica granatum — PMC
• Pomegranate Uses, Benefits & Dosage — Drugs.com Natural Products Database
• Pomegranate Extract — ScienceDirect Topics Overview
• The effects of pomegranate consumption on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis — PubMed